Insulin vs GLP-1 analogues in poorly controlled type 2 diabetic subjects on oral therapy: Ameta-analysis

Medicine and Dentistry

• Adverse Event 8%
• Analysis 8%
• Body Weight 8%
• Combination Therapy 58%
• Glucagon Like Peptide 8%
• Glucagon Like Peptide 1 100%
• Glucagon-Like Peptide-1 Agonist 8%
• Glucose 16%
• Glycated Hemoglobin 8%
• Glycemic 8%
• Glycemic Control 8%
• Hemoglobin A1c 33%
• Hypoglycemia 16%
• Insulin Treatment 25%
• Maturity Onset Diabetes of the Young 8%
• Patient 8%
• Plasma 8%
• Randomized Controlled Trial 33%
• Systolic Blood Pressure 8%
• Therapeutic Procedure 8%
• Type 2 Diabetes 25%
• Weight Loss 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 8%
• Glucagon Like Peptide 8%
• Glucagon Like Peptide 1 Receptor Agonist 8%
• Glucagon-Like Peptide-1 100%
• Glucose 16%
• Glycosylated Hemoglobin 8%
• Hemoglobin A1c 33%
• Hypoglycemia 16%
• Insulin 58%
• Non Insulin Dependent Diabetes Mellitus 8%